Inspired by **patients.**
Driven by **science.**

Sustainable Access

For patients to benefit from our treatment advances, access to new and existing medicines needs to be timely and sustainable for patients and the health systems that serve them. At UCB, we define access as the ability of a patient to obtain the medicine that they need in a timely fashion and without undue burden. Sustainable access means working to ensure that all patients who need our treatments can access them in a way that is socially responsible, economically viable for patients, health-care systems and UCB, as well as environmentally sustainable. In many countries, the time it takes to complete approval and access procedures can cause delays for patients, a delay that should be safely minimized wherever possible.

For patients with severe diseases, timely access can play a big role in improving outcomes and quality of life. At UCB, we believe we have a responsibility not only to continue to innovate to find differentiated solutions for unmet need, but also to work towards ensuring that patients have timely access to our treatments. This means working together, with our partners and with health-care systems, to reduce the number of days between marketing authorization in a country and the date the product is reimbursed so a patient is able to access the treatment. This also means participating and running early access schemes and promoting positive policy and regulatory environments that promote timely access to treatments.

UCB's Values

Our priority is to bring more new differentiated treatment options to people living with severe diseases. We believe that all patients who need our treatments should have access to them now and into the future. This is what we are striving to achieve by 2030 across all countries in which we operate, by collaborating and partnering with health-care systems to deliver for patients. At UCB we look beyond the numbers, to consider the real impact on the individual patients waiting to access our treatments. We believe that everybody who needs them has a right to access treatments in a timely manner, and we put patient experience and patient outcomes at the core of how we measure access. We understand that each patient faces unique circumstances due to their personal situation as well as how their health-care system operates. To help secure access for our treatments, for patients that need them as fast and safely as possible we welcome a diverse set of stakeholders' views on how we can better support and deliver more sustainable treatments which address patients' needs.

UCB's Approach

At UCB, as we pursue timely and equitable access across all our operations, we actively assess not only whether our solutions are available, but whether patients have timely access to them. This information guides all aspects of our decision making, from innovation, to production, to launch. We look at how many countries where we operate have reimbursed our medicines, and to which

patients. We directly measure how many patients our treatments are designed for can have access to them, to deliver on our values. To understand how quickly our medicines reach patients, we benchmark the industry median time taken to reimburse medicines in each country. When we launch a new treatment, we compare the time it takes for a reimbursement decision to be made, and work to reduce the wait as much as possible via our own actions and collaboration. We look holistically at the impact of barriers to access in each country on patients, and work on reducing the burden. Things such as affordability and cost share levels have a real impact on patient access, so we quantify and consider these within each health-care system to do our part to support sustainable access for patients.

Ensuring UCB treatments reach patients

To make sure our treatments are reaching the people that need them, we look at the reimbursement decision taken to see how many of the patients that a treatment was designed for are able to access the treatment they need. We do this through our 'Access Coverage Performance Index', which looks at the rate of availability in each country and combines it with our timely access measures, using all data available from all countries we operate in. This data categorizes the availability of UCB treatments into three possible states: Reimbursement for all patients, reimbursement for some patients, or no reimbursement, showing us where we can improve. As we actively consider the context in which our treatments are launched and our we can collaborate with health-care systems, this enables us to ensure we are doing as much as we can as a company to make our innovative treatments accessible for our patients. We use a 'Time to Access Index', which looks at the number of days it takes for a country to progress from the market authorization of a medication, to a negotiated reimbursement listing or managed access program.

From Innovation to Access

We know that patient affordability, access, and the reimbursement landscape looks different in each country. We consider the context of patient access from day one as we develop our treatments, ensuring that we include appropriate and necessary endpoints in our clinical trials. We think beyond a treatment's launch and consider factors that directly impact patient access, such as reimbursement criteria and patient affordability, and look to design clinical trials to facilitate this access, collaborating with other key stakeholders to bring medicines to patients.

We are also looking into how we can address specific access barriers experienced in low- or lower-middle income countries, and how we can support access for patients in different regions. In Mumbai, India for example, where epilepsy rates are high, we are running a pilot which addresses persisting barriers to treatment ranging from low disease awareness and existing stigma around epilepsy, to restricted capacity in the health-care systems, as well as limited treatment availability and affordability.

If urgency and unmet patient need is high, and UCB has a medicine in development which may be of benefit for patients, UCB has established an Early Access Program. The Access+ program provides access to our treatments through a standard mechanism which receives, reviews, and manages requests for access to our investigational products or products approved by at least one major regulatory body. UCB also participates in national Early Access Programs in collaboration with governments where appropriate, which are tailored to specific circumstances and health systems.

In reviewing the barriers to access at both a country and patient level – we can work to ensure we have delivered against our commitment to support all patients as best we can, from innovation to launch, working to ensure sustainable access for all that need it.

Our Commitments

We have set an ambitious target for all patients who need our treatments in countries where we operate to have access to them by 2030. To get there, we measure access in a meaningful way for patients, and build on that data, constantly striving to improve. We are dedicated to partnering and collaborating with health-care systems to make this a reality for patients.

We are committed to being at the forefront of our industry in delivering for patients, identifying where we can take action to make improvements, and seeking timely reimbursement for our treatments for patients who need.

At UCB, we are also dedicated to improving access for underserved populations. Our goal is that by 2030, all patients who need our medicines in countries where we operate have access to them.